Security
Mirum Pharmaceuticals, Inc. Common Stock · MIRM
MIRMNASDAQCommon stockCurrentCIK 1759425Updated Oct 27, 2026
MIRM price & chart
Loading TradingView…
NASDAQ:MIRM on TradingView ↗About the company
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01
Other Events
Items 8.01
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 785,115,000Source | 667,893,000Source | 1,044,981,000Source | 725,825,000Source | 660,754,000Source | 890,916,000Source | 690,245,000Source | 651,962,000Source | 842,813,000Source | 670,754,000Source | 646,621,000Source | 352,906,000Source |
| Property, Plant and Equipment, NetUSD | 1,277,000Source | 1,212,000Source | 2,251,000Source | 1,177,000Source | 1,101,000Source | 2,412,000Source | 1,108,000Source | 501,000Source | 1,862,000Source | 1,139,000Source | 706,000Source | 914,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 231,895,000Source | 255,794,000Source | 247,388,000Source | 237,870,000Source | 261,768,000Source | 254,154,000Source | 243,845,000Source | 257,443,000Source | 260,921,000Source | 249,819,000Source | 252,925,000Source | 58,954,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 282,021,000Source | 222,969,000Source | 330,728,000Source | 228,122,000Source | 233,245,000Source | 324,907,000Source | 211,822,000Source | 302,843,000Source | 296,683,000Source | 222,503,000Source | 286,326,000Source | 28,003,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 107,132,000Source | 68,530,000Source | 145,360,000Source | 106,836,000Source | 60,430,000Source | 133,113,000Source | 95,852,000Source | 54,999,000Source | 123,330,000Source | 78,286,000Source | 67,968,000Source | 23,994,000Source |
| Inventory, NetUSD | 24,021,000Source | 21,594,000Source | 25,769,000Source | 22,941,000Source | 20,438,000Source | 25,518,000Source | 22,418,000Source | 21,606,000Source | 24,887,000Source | 22,403,000Source | 22,312,000Source | 5,565,000Source |
| Assets, CurrentUSD | 530,575,000Source | 386,626,000Source | 636,310,000Source | 453,398,000Source | 367,829,000Source | 569,436,000Source | 410,818,000Source | 389,465,000Source | 549,684,000Source | 392,788,000Source | 387,541,000Source | 190,225,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 23,874,000Source | 12,057,000Source | 26,890,000Source | 19,069,000Source | 8,590,000Source | 24,546,000Source | 14,874,000Source | 10,017,000Source | 18,140,000Source | 11,784,000Source | 10,935,000Source | 8,947,000Source |
| Operating Lease, Right-of-Use AssetUSD | 8,500,000Source | 9,135,000Source | 12,024,000Source | 8,946,000Source | 8,759,000Source | 12,647,000Source | 7,663,000Source | 680,000Source | 8,741,000Source | 8,675,000Source | 1,284,000Source | 1,431,000Source |
| Other Assets, NoncurrentUSD | 9,918,000Source | 5,380,000Source | 22,244,000Source | 6,842,000Source | 3,972,000Source | 16,181,000Source | 5,474,000Source | 3,873,000Source | 12,018,000Source | 5,382,000Source | 4,165,000Source | 1,382,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 493,069,000Source | 435,869,000Source | 1,055,403,000Source | 470,667,000Source | 431,766,000Source | 648,422,000Source | 456,989,000Source | 417,359,000Source | 528,123,000Source | 445,114,000Source | 397,951,000Source | 210,869,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 5,000Source | 5,000Source | 6,000Source | 5,000Source | 5,000Source | 6,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 4,000Source |
| Retained Earnings (Accumulated Deficit)USD | -661,814,000Source | -620,391,000Source | -1,524,926,000Source | -664,719,000Source | -606,156,000Source | -1,457,699,000Source | -658,858,000Source | -581,518,000Source | -667,544,000Source | -644,181,000Source | -556,239,000Source | -392,824,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 37,000Source | 920,000Source | -674,000Source | 352,000Source | -477,000Source | -28,000Source | -258,000Source | -13,000Source | 351,000Source | -373,000Source | 1,644,000Source | -217,000Source |
| Stockholders' Equity Attributable to ParentUSD | 292,046,000Source | 232,024,000Source | -10,422,000Source | 255,158,000Source | 228,988,000Source | 242,494,000Source | 233,256,000Source | 234,603,000Source | 314,690,000Source | 225,640,000Source | 248,670,000Source | 142,037,000Source |
| Additional Paid in Capital, Common StockUSD | 953,818,000Source | 851,490,000Source | 1,515,172,000Source | 919,520,000Source | 835,616,000Source | 1,700,215,000Source | 892,367,000Source | 816,129,000Source | 981,878,000Source | 870,189,000Source | 803,260,000Source | 535,074,000Source |
| Liabilities and EquityUSD | 785,115,000Source | 667,893,000Source | 1,044,981,000Source | 725,825,000Source | 660,754,000Source | 890,916,000Source | 690,245,000Source | 651,962,000Source | 842,813,000Source | 670,754,000Source | 646,621,000Source | 352,906,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 160,359,000Source | 115,751,000Source | 222,788,000Source | 144,796,000Source | 112,308,000Source | 272,824,000Source | 127,577,000Source | 105,909,000Source | 205,799,000Source | 126,551,000Source | 87,064,000Source | 64,729,000Source |
| Operating Lease, Liability, CurrentUSD | 2,035,000Source | 1,506,000Source | 2,405,000Source | 2,081,000Source | 1,072,000Source | 2,353,000Source | 1,644,000Source | 358,000Source | 2,139,000Source | 1,709,000Source | 1,104,000Source | 931,000Source |
| Accounts Payable, CurrentUSD | 12,167,000Source | 9,545,000Source | 23,427,000Source | 17,657,000Source | 9,842,000Source | 59,399,000Source | 11,639,000Source | 15,983,000Source | 9,614,000Source | 14,618,000Source | 7,416,000Source | 8,690,000Source |
| Operating Lease, Liability, NoncurrentUSD | 7,361,000Source | 8,480,000Source | 10,465,000Source | 7,884,000Source | 8,244,000Source | 11,175,000Source | 7,003,000Source | 328,000Source | 7,516,000Source | 7,972,000Source | 617,000Source | 1,257,000Source |
| Other Liabilities, NoncurrentUSD | 15,981,000Source | 3,972,000Source | 10,917,000Source | 9,054,000Source | 3,972,000Source | 5,915,000Source | 13,900,000Source | 4,287,000Source | 5,011,000Source | 2,509,000Source | 3,849,000Source | 4,532,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 104,700,000Source | — | — | 101,394,000Source | — | — | 89,568,000Source | 196,185,000Source | 110,224,000Source | 78,544,000Source | 54,018,000Source |
| Short-term InvestmentsUSD | 93,527,000Source | 61,476,000Source | 107,563,000Source | 76,430,000Source | 45,126,000Source | 61,352,000Source | 65,852,000Source | — | 86,644,000Source | 57,812,000Source | 0Source | 123,716,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -790,155,000Source | -14,677,000Source | -23,363,000Source | -87,942,000Source | -163,415,000Source | -135,665,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 6,874,000Source | 6,052,000Source | 24,244,000Source | 23,629,000Source | 10,829,000Source | 3,238,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 36,202,000Source | 15,803,000Source | 71,424,000Source | 48,444,000Source | 35,023,000Source | 27,007,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 12,886,000Source | 16,833,000Source | 48,055,000Source | 11,426,000Source | 43,974,000Source | 20,727,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 1,920,000Source | 2,672,000Source | 8,448,000Source | 3,166,000Source | 4,393,000Source | 3,448,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | -6,581,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -228,763,000Source | -1,961,000Source | 55,827,000Source | 10,325,000Source | -70,944,000Source | -120,136,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 212,762,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -11,569,000Source | -16,134,000Source | -23,954,000Source | -90,125,000Source | -107,200,000Source | 7,700,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 664,000Source | 41,000Source | 954,000Source | 993,000Source | 109,000Source | 278,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 270,079,000Source | 6,359,000Source | 40,142,000Source | 17,699,000Source | 336,600,000Source | 109,087,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 28,475,000Source | -10,681,000Source | 75,237,000Source | -63,398,000Source | 158,323,000Source | -3,337,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 12,650,000Source | 12,650,000Source | 6,817,000Source | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 220,000Source | 162,000Source | 2,157,000Source | 1,004,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 18,127,000Source | 11,908,000Source | 30,575,000Source | 18,468,000Source | 57,474,000Source | 15,803,000Source | 71,424,000Source | 48,444,000Source | 35,023,000Source | 27,007,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | 658,000Source | 427,000Source | 454,000Source | 433,000Source | 1,739,000Source | 1,661,000Source | 1,117,000Source | — |
| Amortization of Intangible AssetsUSD | — | — | 6,000,000Source | 5,900,000Source | 6,700,000Source | 5,900,000Source | 6,800,000Source | 6,000,000Source | 23,900,000Source | 23,100,000Source | 10,500,000Source | 2,900,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | -900,000Source | 600,000Source | -1,098,000Source | 658,000Source | 1,720,000Source | 1,231,000Source | -1,764,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | -49,076,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | -262,000Source | 347,000Source | 1,689,000Source | 402,000Source | 475,000Source | 1,029,000Source | 1,936,000Source | 1,030,000Source | 991,000Source | -6,406,000Source |
| InterestExpenseNonoperatingUSD | — | — | 3,606,000Source | 3,586,000Source | 2,618,000Source | 3,589,000Source | 3,616,000Source | 3,596,000Source | 14,389,000Source | 14,311,000Source | — | — |
| Investment Income, InterestUSD | — | — | 3,251,000Source | 3,469,000Source | 3,851,000Source | 3,033,000Source | 3,401,000Source | 3,023,000Source | 12,727,000Source | 13,792,000Source | 13,735,000Source | 3,857,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 2,905,000Source | -14,235,000Source | -67,227,000Source | -5,861,000Source | -790,155,000Source | -14,677,000Source | -23,363,000Source | -87,942,000Source | -163,415,000Source | -135,665,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 2,905,000Source | -14,235,000Source | -67,227,000Source | -5,861,000Source | -790,155,000Source | -14,677,000Source | — | -87,942,000Source | -163,415,000Source | -135,665,000Source |
| Operating ExpensesUSD | — | — | 130,407,000Source | 103,061,000Source | 218,780,000Source | 132,774,000Source | 949,347,000Source | 126,768,000Source | 543,448,000Source | 424,494,000Source | 295,528,000Source | 208,282,000Source |
| Operating Lease, ExpenseUSD | — | — | 600,000Source | 600,000Source | 800,000Source | 600,000Source | 800,000Source | 600,000Source | 2,400,000Source | 1,800,000Source | 800,000Source | 800,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 395,000Source | -1,087,000Source | -24,234,000Source | 86,000Source | 0Source | 2,108,000Source | 2,371,000Source | 1,213,000Source | -2,824,000Source | 365,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 34,797,000Source | 33,526,000Source | 97,425,000Source | 89,026,000Source | 27,329,000Source | 132,322,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 14,480,000Source | 21,289,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 33,892,000Source | 17,433,000Source | 74,425,000Source | 19,894,000Source | 153,000,000Source | 140,300,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 133,010,000Source | 90,377,000Source | 176,243,000Source | 127,785,000Source | 159,882,000Source | 111,585,000Source | 521,312,000Source | 336,888,000Source | 186,374,000Source | 77,062,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 61,910,000Source | 50,545,000Source | 81,469,000Source | 63,286,000Source | 96,330,000Source | 57,706,000Source | 257,030,000Source | 202,221,000Source | 145,880,000Source | 89,066,000Source |
| Operating Income (Loss)USD | — | — | 2,603,000Source | -12,684,000Source | -42,537,000Source | -4,989,000Source | -789,465,000Source | -15,183,000Source | -22,136,000Source | -87,606,000Source | -109,154,000Source | -131,220,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 395,000Source | -1,087,000Source | -24,234,000Source | 86,000Source | 0Source | 2,108,000Source | 2,371,000Source | 1,213,000Source | -2,824,000Source | 365,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 2,643,000Source | -13,888,000Source | -65,538,000Source | -5,459,000Source | -789,680,000Source | -13,648,000Source | -21,427,000Source | -86,912,000Source | -162,424,000Source | -142,071,000Source |
| Income Tax Expense (Benefit)USD | — | — | -262,000Source | 347,000Source | 1,689,000Source | 402,000Source | 475,000Source | 1,029,000Source | 1,936,000Source | 1,030,000Source | 991,000Source | -6,406,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 2,905,000Source | -14,235,000Source | -67,227,000Source | -5,861,000Source | -790,155,000Source | -14,677,000Source | -23,363,000Source | -87,942,000Source | -163,415,000Source | -135,665,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.06Source | -0.3Source | -1.06Source | -0.12Source | -13.43Source | -0.3Source | -0.47Source | -1.85Source | -4Source | -4.01Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.05Source | -0.3Source | -1.06Source | -0.12Source | -13.43Source | -0.3Source | -0.47Source | -1.85Source | -4Source | -4.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 50,639,231Source | 47,782,619Source | 63,374,183Source | 49,726,823Source | 58,851,021Source | 48,889,058Source | 50,198,304Source | 47,522,594Source | 40,885,124Source | 33,839,072Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 56,993,841Source | 47,782,619Source | 63,374,183Source | 49,726,823Source | 58,851,021Source | 48,889,058Source | 50,198,304Source | 47,522,594Source | 40,885,124Source | 33,982,493Source |
| Interest Expense (non-operating)USD | — | — | 3,606,000Source | 3,586,000Source | 2,618,000Source | 3,589,000Source | 3,616,000Source | 3,596,000Source | 14,389,000Source | 14,311,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 6,000,000Source | 5,900,000Source | 6,700,000Source | 5,900,000Source | 6,800,000Source | 6,000,000Source | 23,900,000Source | 23,100,000Source | 10,500,000Source | 2,900,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,936,000Source | 1,030,000Source | 991,000Source | 175,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -24,877,000Source | -89,937,000Source | -164,953,000Source | -142,661,000Source |
| Investment Income, InterestUSD | — | — | 3,251,000Source | 3,469,000Source | 3,851,000Source | 3,033,000Source | 3,401,000Source | 3,023,000Source | 12,727,000Source | 13,792,000Source | 13,735,000Source | 3,857,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 2,905,000Source | -14,235,000Source | -67,227,000Source | -5,861,000Source | -790,155,000Source | -14,677,000Source | — | -87,942,000Source | -163,415,000Source | -135,665,000Source |
| Operating ExpensesUSD | — | — | 130,407,000Source | 103,061,000Source | 218,780,000Source | 132,774,000Source | 949,347,000Source | 126,768,000Source | 543,448,000Source | 424,494,000Source | 295,528,000Source | 208,282,000Source |
| Operating Lease, ExpenseUSD | — | — | 600,000Source | 600,000Source | 800,000Source | 600,000Source | 800,000Source | 600,000Source | 2,400,000Source | 1,800,000Source | 800,000Source | 800,000Source |
| Interest Expense, Debt | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-293762
Filing attachments
d113366dex41.htm · 8-K · 2026-05-18
EX-4.1 2 d113366dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 EXECUTION VERSION MIRUM PHARMACEUTICALS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of May 15, 2026 0.00% Convertible Senior Notes due 2032 TABLE OF CONTENTS Page Article 1. Definitions;…
Read attachment ↗d113366dex991.htm · 8-K · 2026-05-18
EX-99.1 3 d113366dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering FOSTER CITY, Calif. - May 12, 2026 - Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced its intention to offer, subject to market conditions and other factors, $600.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reason…
Read attachment ↗d113366dex992.htm · 8-K · 2026-05-18
EX-99.2 4 d113366dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes FOSTER CITY, Calif. - May 12, 2026 - Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) in a private placement (the “offering”) t…
Read attachment ↗mirm-20260408xex991.htm · 8-K/A · 2026-04-08
Index to Consolidated Financial Statements Audited Consolidated Financial Statements as of and for the Year Ended December 31, 2025: ──────────────────────────────────────────────────────────────────────────────────────────────────────── Page Independent Auditors’ Report F-2 Consolidated Balance Sheet …
Read attachment ↗mirm-20260408xex992.htm · 8-K/A · 2026-04-08
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On December 6, 2025, Mirum Pharmaceuticals, Inc. (the “Company”, “Mirum”) entered into an Agreement and Plan of Merger and Reorganization (“Merger Agreement”) with Bluejay Therapeutics, Inc. (“Bluejay”). Bluejay is a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases. On January 23, 2026 (the “Closing Date”), Mirum completed the acquisition of B…
Read attachment ↗d35336dex991.htm · 8-K · 2026-01-26
Exhibit 99.1 Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - Adds brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations to Mirum’s portfolio - Topline Phase 3 results expected in 2H 2026 FOSTER CITY, Calif. - January 26, 2026 - Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a leading rare disease company, today announced the successful completion of its acquisition of Bluejay Therape…
Read attachment ↗